News India Times

www.newsindiatimes.com – that’s all you need to know Community News India Times (January 24, 2026 - January 30, 2026) January 30, 2026 9 J aswant Singh Gill, 57, of Sacramento, pleaded guilty January 15, 2026, to one count of wire fraud for orchestrating an investment fraud scheme, U.S. At- torney Eric Grant of the Eastern District of California announced. According to court documents, between May 2024 and June 2025, Gill was the Chief Executive Officer of Kismet Capital Partners LLC. Using Kismet Capital, Gill executed a scheme to defraud that involved making false representations and promises in exchange for purported investments. Gill falsely represented to investors that Kismet Capital was an investment firm with about 20 employees. He falsely promised that funds invested into Kismet Capital would be used solely for investment pur- poses, and the investor would receive a specific monthly rate of return. Based on the promises, a victim investor sent approximately $777,470 in the form of cash and wire transfers to be invested into Kismet. The victim obtained these funds from sources including personal loans, loans against an IRA, and a home equity line of credit. Gill also used at least one of the victim’s credit cards to obtain cash advances. Instead of using the funds for investment purposes, Gill used the stolen funds for his own personal use in- cluding, paying for dinners at restaurants, paying a per- sonal driver, and purchases of luxury items. During the time that Gill was stealing the investor’s funds, Gill falsely assured the investor that their investment was growing, when in fact, the investment was not growing. Also based on court records, Gill committed this scheme to defraud while on federal supervised release that was imposed after Gill’s 2018 conviction for wire fraud in another federal judicial district. The Federal Bureau of Investigation conducted the investigation. Assistant U.S. Attorney Nchekube Onyima is prosecuting the case. Gill is scheduled to be sentenced on April 2, 2026, before Chief U.S. District Judge Troy L. Nunley. Gill faces a maximum statutory penalty of 20 years in prison and a $250,000 fine. The actual sentence, however, will be determined at the discretion of the court after consider- ation of any applicable statutory factors and the federal Sentencing Guidelines, which take into account a num- ber of variables. Sacramento Man Pleads Guilty To Defrauding An Investor Of $777,470 By a StaffWriter PHOTO:DREAMSTIME Federal Jury Finds Memphis Physician Guilty Of Adulterated And Misbranded Medical Devices And Health Care Fraud -MEMPHIS, TN (JANUARY 8, 2026) A fter a three-and-a-half-week trial and five days of deliberations, a federal jury found Memphis physician Sanjeev Kumar guilty of eighteen counts of adultera- tion of medical devices, sixteen counts of misbranding medical devices, and six counts of health care fraud. From 2019 to 2024, Kumar submitted and caused his employees to submit fraudulent claims to Medicare and Medicaid for hysteros- copy with biopsy procedures that were not medically necessary and conducted with adulterated devices. United States Attorney D. Michael Dunavant, of the Western District of Tennessee, announced the verdict today. “This doctor put profit ahead of pa- tients, targeting a vulnerable population of women, telling them he needed to con- duct invasive gynecological procedures to diagnose them with cancer and risking infection to those patients by reusing the same insanitary medical devices on them again and again,” stated D. Michael Dunavant, U.S. Attorney. “If we allow doc- tors to bilk Medicare and Medicaid to pad their profits by performing unsupported medical procedures with filthy devices — each and every American taxpayer eats the cost. But the harm is most felt by the victim-patients who deserved better, and the American women on Medicare and Medicaid are entitled to quality care. Kumar’s blatant disregard for his patients’ health has led to his conviction on mul- tiple federal charges. My office is proud to work with the investigative agencies that helped bring this man to justice.” Kumar was a gynecologic oncologist who operated Poplar Avenue Clinic, a women’s health clinic in Memphis, Ten- nessee. Between September of 2019 and April of 2024, Kumar and the advanced practitioners he supervised performed over 15,000 hysteroscopies with biopsy on 5,559 Medicare and Medicaid patients. The hysteroscopy with biopsy is an in- office procedure where a hysteroscope is inserted into the vagina, pushed through the cervix, and into the uterus. A grasper or pipelle is then inserted through the hysteroscope to take a sample of the endometrial lining of the uterus. The pro- cedure is used to diagnose endometrial cancer. The FDA cleared several single-use hysteroscopes and graspers, as well as reusable hysteroscopes to complete these procedures. The single-use devices were to be used once and then discarded. To correctly disinfect the devices cleared for reprocess- ing, Kumar had to strictly follow manu- facturer instructions. Kumar routinely failed to subject the reusable devices to vital reprocessing steps between patient use, thereby, endangering patient safety. The single-use devices, even if they had been correctly reprocessed, had to be labeled as such, and Kumar did not label them. Kumar purchased less than 200 new single-use hysteroscopes, and 3 of the 6 single-use graspers of a certain type he purchased in 2019 were still in use in the office in April 2024. “FDA’s requirements for safe use of medical devices are in place to protect the health of the public. When healthcare providers disregard safety information, including single-use and single-user designations, resulting in the adulteration and misbranding of medical devices, they put patients’ health at risk,” said Acting Special Agent in Charge Juan Berrios, FDA Office of Criminal Investigations, Miami Field Office. “We will continue our vigilance in protecting the U.S. consum- ers’ and patients’ right to safe medical products.” Kumar billed more than $41 million for the hysteroscopy with biopsy procedures between September 2019 and April 2024. He netted more than $4.8 million for this procedure fromMedicare and Medicaid alone. That amount does not include any hysteroscopy with biopsy procedures performed on patients with private health care insurance. “Profits should never come before patient safety,” said TBI Director David Rausch. “When healthcare providers side- step best safety practices for the sake of their bottom line, patients pay the price. I’m proud of the work of our team at TBI and all stakeholders to hold this provider accountable and hope it sends a mes- sage: We won’t stop rooting out bad actors trying to take advantage of the system meant to support the elderly and our most vulnerable.” “Health care providers have a solemn duty to prioritize their patients’ well-being and uphold the principle of ‘do no harm.’ When they violate this trust and endanger those in their care, they will be held ac- countable,” said Kelly Blackmon, Special Agent in Charge at the U.S. Department of Health and Human Services Office of Inspector General (HHS-OIG). “Ensuring the safety of Medicare and Medicaid ben- eficiaries is our top priority, and we will continue to work diligently with our law enforcement partners to safeguard these vital programs.” “This guilty verdict underscores our commitment to pursuing those who abuse the health care system for personal profit,” said Special Agent in Charge Jo- seph E. Carrico of the FBI Nashville Field Office. “The FBI and our law enforce- ment partners will continue to root out health care fraud schemes and hold those accountable who not only waste valu- able resources but also jeopardize patient safety and trust.” Sentencing is set on April 9, 2026 before Chief United States District Judge Sheryl H. Lipman. Kumar faces a maximum term of imprisonment of 10 years for each Health Care Fraud count and three years for each Adulteration and Misbranding of Medical Devices count. The United States Department of Health and Human Services Office of the Inspector General (HHS-OIG), the United States Food and Drug Administration Of- fice of Criminal Investigations (FDA-OCI), the Tennessee Bureau of Investigation (TBI), and the Federal Bureau of Investi- gation (FBI) led the investigation, which was initiated by the Tennessee Attorney General. Assistant U.S. Attorneys Lynn Crum, Scott Smith, and Sarah PazarWilliams prosecuted the case. Press Release, U.S. Attorney’s Office, Western District of Tennessee